Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remdesivir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remdesivir SCHEMBL31156820 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712238 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712227 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL22143154 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL23685886 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL17712269 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24494884 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24494885 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL24611640 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 | |
| Remdesivir SCHEMBL30001735 | 1.00 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9KRASRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4331677-A2 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-3595672-B1 | COMPOUNDS FOR USE IN METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200376014-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-10682368-B2 | Methods of treating feline coronavirus infections | GILEAD SCIENCES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| WO-2019053696-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018169946-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | TMPRSS2 664/4885CYP3A4 573/4885CYP2C9 401/4885 |
| US-10682368-B2 | Methods of treating feline coronavirus infections | SARS1, CPN1, CAT | TMPRSS2 62/4885CYP3A4 1929/4885CYP2C9 4334/4885 |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | TMPRSS2 867/4885CYP3A4 600/4885CYP2C9 483/4885 |
| US-20200376014-A1 | METHODS OF TREATING FELINE CORONAVIRUS INFECTIONS | CAT, ACE, ACE2 | TMPRSS2 9/4885CYP3A4 3347/4885CYP2C9 2792/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | TMPRSS2 867/4885CYP3A4 600/4885CYP2C9 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.